Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: Efficiency and possible additional pathways

Investigative Ophthalmology and Visual Science

Volumn 49, Issue 10, 2008, Pages 4523-4527

  Klettner, Alexa ^a   Roider, Johann ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; APTAMER; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANIMAL CELL CULTURE; ANIMAL TISSUE; ARTICLE; CHOROID; CONTROLLED STUDY; DILUTION; DOWN REGULATION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE; IN VITRO STUDY; NONHUMAN; ORGAN CULTURE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RETINA; RETINA MACULA AGE RELATED DEGENERATION; SIGNAL TRANSDUCTION; SUPERNATANT; SWINE; WESTERN BLOTTING; ANIMAL; COMPARATIVE STUDY; CULTURE TECHNIQUE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; ORGAN CULTURE TECHNIQUE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; APTAMERS, NUCLEOTIDE; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CHOROID; ENZYME-LINKED IMMUNOSORBENT ASSAY; ORGAN CULTURE TECHNIQUES; PIGMENT EPITHELIUM OF EYE; RETINA; SWINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 53449095951     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2055     Document Type: Article

References (24)

1. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer D. Pegaptanib for neovascular age-related macular degeneration. N Eng J Med. 2004;351:2805-2816. (Pubitemid 40051904)
2. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112:1035-1047. (Pubitemid 40797459)
3. Krämer I, Lipp HP. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther. 2007;32:1-14. (Pubitemid 46213936)
4. Campochiaro PA. Targeted pharmacotherapy of retinal diseases with ranibizumab. Drugs Today. 2007;43:529-537.
5. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular disease. Ann Pharmacother. 2007;41:614-625.
6. Kobuch K, Herrmann WA, Framme C, Sachs HG, Gabel VP, Hillenkamp J. Maintenance of adult porcine retina and retinal pigment epithelium in perfusion culture: characterisation of an organotypic in vitro model. Exp Eye Res. 2008;86:661-668.
7. Spitzer MS, Yoeruek E, Sierra A, et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefe's Arch Clin Exp Ophthalmol. 2007;245:1837-1842. (Pubitemid 350154019)
8. Klettner A, Herdegen T. The immunophilin-ligands FK506 and V-10367 mediate neuroprotection by heat shock response. Br J Pharmacol. 2003;138:1004-1012. (Pubitemid 36390658)
9. Liu W, Parikh A, Stoeltzing O, et al. Upregulation of neuropilin-1 by basic fibroblast growth factor enhances vascular smooth muscle cell migration in response to VEGF. Cytokine. 2005;32:206-212. (Pubitemid 43144652)
10. Fuh G, Wu P, Liang WC, et al. Structure-function studies of two synthetic anti-VEGF Fabs and comparison with the Avastin Fab. J Biol Chem. 2006;281:6625-6631.
11. Keyt BA, Berleau LT, Nguyen HV, et al. The carboxy-terminal domain (111-165) of VEGF is critical for its mitogenic potency. J Biol Chem. 1996;271:7788-7795.
12. Muller YA, Christinger HW, Keyt BA, de Vos AM. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 A resolution: multiple copy flexibility and receptor binding. Structure. 1998;6:1153-1167.
13. Lee JH, Canny MD, De Erkenez A, et al. Therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. Proc Natl Acad Sci U S A. 2005;102:18902-18907. (Pubitemid 43049539)
14. Presta LG, Chen H, O'Connor SJ, et al. Humanisation of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-4599.
15. Lowe J, Araujo J, Yang J, Reich M, et al. Ranibizumab inhibits multiple forms of biologically active VEGF in vitro and in vivo. Exp Eye Res. 2007;85:425-430.
16. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for VEGF. Cell. 1998;92:735-745.
17. Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-VEGF antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26:859-870. (Pubitemid 44547437)
18. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113:1695-1705. (Pubitemid 44442453)
19. Thomas EL. Microdose intravenous bevacizumab for treating retinal vascular disease (Abstract). Presented at the 7th International Symposium on Ocular Pharmacology and Therapeutics. 2008:A-32.
20. del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems: a shift to the posterior segment. Drug Discov Today. 2008;13:135-143.
21. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparison of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pharmacol. 1999;27:536-544. (Pubitemid 29446822)
22. Heiduschka P, Fietz H, Hofmeister S, et al. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007;48:2814-2823. (Pubitemid 351261238)
23. Shahar J, Avary RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina. 2006;26:262-269. (Pubitemid 44318177)
24. Zhao B, Ma A, Cai J, Boulton M. VEGF-A regulates the expression of VEGF-C in human retinal pigment epithelial cells. Br J Ophthalmol. 2006;90:1052-1059. (Pubitemid 44140191)